Skip to content
Review Open access

Lactylation Remodels Tumorigenesis, Immune Microenvironment, and Therapeutic Response

Sep 2026 · Current Issues in Molecular Biology · Vol 48 · 0 citations · 152 references
Medicine

TL;DR

This review systematically summarizes the molecular mechanisms and enzymatic basis of lactylation, as well as its regulatory functions in core cancer hallmarks and the immune microenvironment, evaluates the translational prospects of targeting the lactate–lactylation axis, and discusses the key scientific questions and future research directions currently facing the field.

Abstract

Lysine lactylation (Kla) is a lactate-driven post-translational modification that covalently links lactyl groups to lysine residues, directly coupling cellular metabolic states to gene expression regulation and protein functional remodeling. Since its first report in 2019, extensive studies have confirmed that lactylation is broadly present on histones and thousands of non-histone substrates. In the context of tumor biology, lactylation reinforces glycolysis through positive feedback loops, suppresses oxidative phosphorylation, remodels lipid and glutamine metabolism, and exerts regulatory functions in autophagy, pyroptosis, ferroptosis, and apoptosis, thereby comprehensively participating in tumor cell proliferation, metabolic adaptation, cell death resistance, and invasion and metastasis. Within the tumor microenvironment, lactylation constructs an immune evasion barrier by upregulating immune checkpoints, including programmed death-ligand 1 (PD-L1), driving tumor-associated macrophage polarization toward the M2 phenotype, inducing CD8+ T cell exhaustion, and enhancing regulatory T cell suppressive function. Strategies targeting lactate production (lactate dehydrogenase A (LDHA) inhibitors), lactate transport (monocarboxylate transporter (MCT) inhibitors), and the lactylation enzymatic machinery (p300/CBP inhibitors, histone deacetylase (HDAC) inhibitors) have shown promising results in preclinical models, and a limited number of agents, including the MCT1 inhibitor AZD3965 and the p300/CBP inhibitor CCS1477, have entered early-phase clinical trials primarily for safety and tolerability assessment. This review systematically summarizes the molecular mechanisms and enzymatic basis of lactylation, as well as its regulatory functions in core cancer hallmarks and the immune microenvironment, evaluates the translational prospects of targeting the lactate–lactylation axis, and discusses the key scientific questions and future research directions currently facing the field.

Read PDF

Similar papers

Review Sep 2026

Lactate and lactylation in cancer: metabolic regulation, immune modulation, and therapeutic opportunities.

A deeper understanding of lactate flux and lactylation-dependent vulnerabilities may enable biomarker-guided combinations that integrate metabolic intervention, epigenetic modulation, and immuno-oncology for precision cancer therapy.

Jia-Yi Chen, An-Qi He, Si-Yi Zhu et al. · 0 citations
Review Open access Oct 2026

Lysine lactylation in glioma: from metabolic stress to epigenetic remodeling and therapeutic resistance

This review systematically summarizes current progress on the lactate-Kla axis in glioma, encompassing the basis of lactate metabolism, the molecular regulatory network of Kla, and the distinct yet coordinated functions of histone and non-histone lactylation.

Xiao-Song Hu, Li Yang, Yang-Hao Hu et al. · 0 citations
Review Open access Aug 2026

Lactate metabolism and protein lactylation in inflammatory and tumor microenvironments

Lactate and lactate-mediated protein lactylation are no longer viewed merely as accompanying phenomena of enhanced glycolysis, hypoxic responses, or tissue acidification. They are now recognized as an important regulatory axis that links local metabolic stress to chromatin regulation and altered protein function. With...

Hua-Qing Lei, Yulin Bai, Jianbo Tang et al. · 0 citations
Review Open access Oct 2026

Lactylation in glioblastoma: mechanisms and therapeutic perspectives

Glioblastoma (GBM) is one of the most aggressive primary malignant tumors in the central nervous system. It is characterized by significant metabolic reprogramming, obvious glycolysis dependence, and excessive lactate accumulation. Rather than being merely a metabolic by-product, lactate is increasingly recognized as a...

Long Huang, Bo-Yu Huang, Shi-Zhen Kuang et al. · 0 citations
Review Oct 2026

Non-histone protein lactylation in cancer metastasis: From metabolic reprogramming to therapeutic targeting.

How non-histone lactylation regulates the metastatic cascade is synthesized using a three-tier confidence framework distinguishing fully characterized circuits from proteomic screening hits, and therapeutic strategies ranging direct lactylation machinery inhibitors from indirect lactate-axis modulators are discussed.

Mithu Howlader, A. Akinyemi, Md Rakibul Alam et al. · 0 citations
Open access Oct 2026

Leucine-derived isovaleric acid remodels the tumor microenvironment by degrading EIF3I.

Metabolic reprogramming and immune evasion are hallmarks of cancer. Although leucine is well known for regulating protein synthesis, its role in immunometabolic interactions within the tumor microenvironment (TME) remains unclear. In this study, we found that leucine supplementation significantly inhibited tumor growth...

Jia-Hui Xu, Zi-Ming Wang, Chun-Li Wei et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.